Agilent Technologies Inc. (NYSE: A) today introduced the IQFISH FFPE Hybridization buffer, which enables one-hour hybridization for FISH processing on formalin fixed paraffin embedded (FFPE) tissue samples. The IQ technology, originally developed by Dako, was previously available only to anatomic pathology labs. Now, with the IQFISH FFPE Hybridization buffer offered as a standalone product, cytogenetic labs have access to the IQ technology and much faster results. “The IQFISH FFPE Hybridization Buffer will revolutionize FISH processing time on FFPE samples,” said Jacob Thaysen, vice president and general manager for Agilent’s Diagnostics and Genomics business. “By reducing the hybridization processing step from the industry standard of two days to just one hour, our customers can get their results faster and without compromising signal strength.” For more information about Dako IQFISH Hybridization buffer, visit www.dako.com. About Dako – An Agilent Technologies Company Dako, based in Denmark, is a global leader in tissue-based cancer diagnostics. Hospital and research laboratories worldwide use Dako’s reagents, instruments, software and expertise to make accurate diagnoses and determine the most effective treatment for cancer patients. Dako, with 1,200 employees, operates in more than 100 countries. Dako became part of Agilent Technologies in June, 2012. Information about Dako is available at www.dako.com. About Agilent Technologies Agilent Technologies Inc. (NYSE: A) is the world’s premier measurement company and a technology leader in chemical analysis, life sciences, diagnostics, electronics and communications. The company’s 20,500 employees serve customers in more than 100 countries. Agilent had revenues of $6.9 billion in fiscal 2012. Information about Agilent is available at www.agilent.com. NOTE TO EDITORS: Further technology, corporate citizenship and executive news is available at www.agilent.com/go/news.